Skip to main content
NanoRepro AG logo

NanoRepro AG — Investor Relations & Filings

Ticker · NN6 ISIN · DE0006577109 LEI · 3912008FCA63AGIMEV74 F Manufacturing
Open in API
Filings indexed 415 across all filing types
Latest filing 2016-01-13 Audit Report / Informat…
Country DE Germany
Listing F NN6

About NanoRepro AG

https://www.nanorepro.com/en/

NanoRepro AG is a company specializing in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The products are designed for both home and professional use. The company's portfolio covers various health areas, including family planning, preventive healthcare, disease detection, food intolerances, allergies, and infectious diseases. The primary goal is to provide accuracy in self-diagnostics for rapid disease detection and health monitoring.

Recent filings

Filing Released Lang Actions
Datum:13.01.2016
Audit Report / Information Classification · 98% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for Oehmichen Optik AG for the fiscal year 2014. It contains a balance sheet (Bilanz) and notes (Anhang) detailing assets, liabilities, and accounting principles. While it is a financial report, it is not a full 10-K (which is specific to US public companies) nor an interim report. Given the structure and content, it represents the core financial reporting for the year, which aligns best with the 'Annual Report' (10-K) category in this taxonomy, as it serves as the official yearly financial disclosure. FY 2014
2016-01-13 German
NanoRepro AG gibt Vertriebsvereinbarung mit der osterreichischen AQUENTA GmbH fur das Vertragsgebiet Iran bekannt
Regulatory Filings Classification · 100% confidence The document is a press release dated January 5, 2016, announcing a distribution agreement between NanoRepro AG and AQUENTA GmbH for the Iranian market. It details the products involved, the expected contract value, and includes commentary from management. This type of announcement, which details a specific business development (a new partnership/agreement) rather than routine financial results (ER, IR, 10-K) or mandatory regulatory disclosures (like insider trading or major shareholdings), fits best under the general category of corporate news or regulatory filings. Since it is a specific business announcement that doesn't fit the other specialized codes (like M&A, Financing, Dividend), and it is not a report itself but an announcement, the most appropriate classification is Regulatory Filings (RNS) as a general corporate news item distributed via DGAP, which often serves as a fallback for non-standard announcements.
2016-01-05 German
NanoRepro AG schliet Vertriebsvereinbarung mit Excellent Healthcare Services fur den Mittleren Osten und Nordafrika
Regulatory Filings Classification · 100% confidence The document is a news release dated December 16, 2015, announcing that NanoRepro AG has signed a distribution agreement with Excellent Healthcare Services for the Middle East and North Africa. It is characterized by a headline, key bullet points summarizing the agreement, quotes from management, and details about the partner and the expected revenue impact. The header 'DGAP-News' indicates it is a regulatory news distribution, but the content itself is a specific corporate action announcement (a new partnership/agreement). This type of announcement, detailing a significant business development that is not a financial report (like 10-K or IR), management change (MANG), or capital event (CAP/SHA), fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially 'LTR' if it were a legal matter, but here it is a commercial agreement. Given the options, RNS serves as the best fit for a general, non-standard corporate news release distributed via a regulatory service (DGAP). It is not an Earnings Release (ER), Interim Report (IR), or a specific report like AR or 10-K.
2015-12-16 German
Datum:23.11.2015
Audit Report / Information Classification · 98% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for NanoRepro AG for the fiscal year 2014. It contains a balance sheet (Bilanz), notes to the financial statements (Anhang zum Jahresabschluss), and details regarding accounting methods, assets, liabilities, and board composition. While it is not a full 10-K (which is a US-specific regulatory filing), it functions as the primary annual financial reporting document for a German company, which falls under the 'Annual Report' category in this classification schema. FY 2014
2015-11-23 German
NanoRepro AG: NanoRepro AG gibt neue Vertriebspartnerschaft mit der JFGH Ltda. fur den Wachstumsmarkt Brasilien bekannt
Regulatory Filings Classification · 100% confidence The document is a press release dated November 20, 2015, announcing a new distribution partnership between NanoRepro AG and JFGH Ltda. for the Brazilian market. It uses keywords like "Pressemitteilung" (Press Release), "DGAP-News," and discusses a strategic agreement ("Vereinbarung"). This type of announcement, detailing a business development or partnership rather than financial results (ER/IR), management changes (MANG), or capital structure events (CAP/SHA), fits best under the general category for regulatory announcements or news releases that don't fit a more specific financial filing type. Since it is a specific business announcement distributed via a news service (DGAP), and it is not a formal regulatory filing like a 10-K or a specific report like an AR or IR, the most appropriate classification is Regulatory Filings (RNS) as the general category for miscellaneous corporate news releases not covered elsewhere.
2015-11-20 German
NanoRepro AG gibt Exklusivvertrag uber funf Jahre mit Global Pharma Serbien fur elf Schnelltests bekannt
Regulatory Filings Classification · 100% confidence The document is a press release dated November 5, 2015, announcing a five-year exclusive distribution agreement between NanoRepro AG and Global Pharma Serbien for eleven rapid tests. It contains keywords like "Pressemitteilung" (Press Release), "Schlagwort(e): Vereinbarung" (Keyword(s): Agreement), and details about a new business contract. This type of announcement, detailing a significant business development or contract, does not fit the specific financial report codes (10-K, IR, ER) or governance codes (DEF 14A, CGR). It is a general corporate announcement. Since it is not a standard regulatory filing like a 10-K or a specific financial result release, and it details a strategic business agreement, it is best classified as a general Regulatory Filing (RNS) as it is a broad announcement distributed via DGAP, or potentially a Capital/Financing Update (CAP) if the contract implied a major capital shift, but the primary nature is a partnership announcement. Given the options, RNS serves as the best general corporate news category for significant, non-standard announcements not covered elsewhere. However, since it is a specific business agreement announcement, and not a mandatory regulatory filing like a director's dealing or a major shareholding change, RNS is the most appropriate fallback for general corporate news distribution.
2015-11-05 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.